Condition: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder · Sponsor: Timothy Voorhees
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. Tafasitamab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving the combination of tafasitamab and rituximab may work better in treating patients with post-transplant lymphoproliferative disorder.
This description comes directly from the study's public registry record.
The Ohio State Comprehensive Cancer Center · 800-293-5066 · OSUCCCClinicaltrials@osumc.edu
Always discuss trial participation with your own doctor first.
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| University of North Carolina-Hillsborough Campus | Hillsborough, North Carolina, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05786040